Purity≥95% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; VHH-Fc; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab182769-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $49.90 | |
| Ab182769-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $249.90 | |
| Ab182769-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $649.90 | |
| Ab182769-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,029.90 |
Purity≥95% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; VHH-Fc; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Letolizumab (anti-TNFSF5) - Primary antibody, specific to CD40LG, Human IgG1 |
|---|---|
| Specifications & Purity | Low Endotoxin, Azide Free, Validated, Recombinant, Carrier Free, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | CD40LG |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, Low Endotoxin, Recombinant, Validated |
| Product Description | Letolizumab (anti-TNFSF5) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab (anti-TNFSF5) reduces rejection, thromboembolism and prolongs the survival time. |
| Isotype | VHH-Fc |
|---|---|
| SDS-PAGE | 26.3 kDa (Light Chain) & 53.0 kDa (Heavy Chain), under reducing conditions; 205.5 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 1450981-87-9 |
Letolizumab (anti-TNFSF5) (Ab182769) - Flow
Flow Cytometry analysis of pLVX-puro-SYMX10-TNFSF5(CD40L)-FL-HEK293 cells labelling TNFSF5 with Letolizumab (anti-TNFSF5) (Ab182769), and negative control protein respectively, washed and then followed by PE and analyzed with the FACS EC
₅₀
is 0.05 nM.
Letolizumab (anti-TNFSF5) (Ab182769) - ELISA
Immobilized Recombinant Human CD40 Ligand protein (rp169583) at 1.0 μg/mL can bind Letolizumab (anti-TNFSF5) (Ab182769) with the EC
₅₀
of 11.26 ng/mL.
Letolizumab (anti-TNFSF5) (Ab182769) - SEC
The purity of Letolizumab (anti-TNFSF5) (Ab182769) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0708870 | Certificate of Analysis | Jul 29, 2024 | Ab182769 |
| ZJ24F0708869 | Certificate of Analysis | Jul 29, 2024 | Ab182769 |
| ZJ24F0708868 | Certificate of Analysis | Jul 29, 2024 | Ab182769 |
